Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at Upcoming Scientific Conferences
27 October 2022 - 7:30AM
Business Wire
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading
clinical-stage immunotherapy company focused on developing
innovative treatments for autoimmune and inflammatory diseases will
have poster presentations for ALPN-303's phase 1 study (RUBY-1) at
upcoming scientific conferences.
American Society of Nephrology: Kidney Week 2022
Date/Time: November 3, 2022, at 10:00 a.m. - 12:00 p.m. EDT
Poster Title: Phase 1 Study in Healthy Adults of the Safety,
Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a
Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune
Glomerulonephritides (GN) Poster Number: TH-PO499 Session
Name: Glomerular Diseases: Clinical Outcomes, Trials – I
American College of Rheumatology Convergence 2022
Date/Time: November 12, 2022, at 9:00 a.m. – 10:30 a.m. EST
Poster Title: A Randomized Placebo-Controlled Phase 1 Study
in Healthy Adult Volunteers of the Safety, Tolerability,
Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Potent Dual
BAFF/APRIL Antagonist for the Treatment of Systemic Lupus
Erythematosus and Other Autoantibody-Associated Diseases Poster
Number: 0987 Session Type: Poster Session B Session
Title: SLE – Treatment Poster
About ALPN-303 and the RUBY-1 Study
ALPN-303 is a dual antagonist of the BAFF (B cell activating
factor) and APRIL (a proliferation inducing ligand) cytokines,
which play key roles in the activation and survival of B cells.
Based upon an engineered TACI (transmembrane activator and CAML
interactor) domain, ALPN-303 exhibits greater potency in
preclinical studies versus wild-type TACI-based comparators, as
well as other inhibitors of BAFF and/or APRIL alone. ALPN-303 is in
development for multiple B cell and/or autoantibody-related
diseases, such as systemic lupus erythematosus,
glomerulonephritides, and autoimmune cytopenias.
RUBY-1 (NCT05034484) is a phase 1, randomized,
placebo-controlled study in healthy adult volunteers designed to
evaluate the safety, tolerability, pharmacokinetics, and
pharmacodynamics of single doses of intravenously and
subcutaneously administered ALPN-303. Initial data show ALPN-303 to
be well tolerated up to 960 mg with dose-dependent pharmacokinetics
and reductions in circulating immunoglobulins and
antibody-secreting cells, supporting the use of a once every
four-week dose regimen for subsequent studies.
About Alpine Immune Sciences
Alpine Immune Sciences is committed to leading a new wave of
immune therapeutics. With world-class research and development
capabilities, a highly productive scientific platform, and a proven
management team, Alpine is seeking to create first- or
best-in-class multifunctional immunotherapies via unique protein
engineering technologies to improve patients’ lives. Alpine has
entered into strategic collaborations with leading global
biopharmaceutical companies and has a diverse pipeline of clinical
and preclinical candidates in development. For more information,
visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on
Twitter and LinkedIn.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
not based on historical fact and include statements regarding our
platform technology and potential therapies; the potential
efficacy, safety profile, future development plans, addressable
market, regulatory success, and commercial potential of our product
candidates; and the timing of our public presentations and
potential publication of future clinical data. Forward-looking
statements generally include statements that are predictive in
nature and depend upon or refer to future events or conditions and
include words such as “may,” “will,” “should,” “would,” “expect,”
“plan,” “intend,” and other similar expressions, among others.
These forward-looking statements are based on current assumptions
that involve risks, uncertainties, and other factors that may cause
actual results, events, or developments to be materially different
from those expressed or implied by such forward-looking statements.
These risks and uncertainties, many of which are beyond our
control, include, but are not limited to: clinical trials may not
demonstrate safety and efficacy of any of our product candidates;
our ongoing discovery and preclinical efforts may not yield
additional product candidates; our discovery-stage and preclinical
programs may not advance into the clinic or result in approved
products; any of our product candidates may fail in development,
may not receive required regulatory approvals, or may be delayed to
a point where they are not commercially viable; we may not achieve
additional milestones in our proprietary or partnered programs; the
impact of competition; adverse conditions in the general domestic
and global economic markets; the impact of the COVID-19 pandemic on
our business, research and clinical development plans and timelines
and results of operations, including the impact on our clinical
trial sites, collaborators, and contractors who act for or on our
behalf, may be more severe and prolonged than currently
anticipated; as well as the other risks identified in our filings
with the Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof and we undertake no
obligation to update forward-looking statements, and readers are
cautioned not to place undue reliance on such forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221026006010/en/
Temre Johnson (Investors) Alpine Immune Sciences, Inc.
ir@alpineimmunesciences.com
Kelli Perkins (Media) Red House kelli@redhousecomms.com
Alpine Immune Sciences (NASDAQ:ALPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alpine Immune Sciences (NASDAQ:ALPN)
Historical Stock Chart
From Apr 2023 to Apr 2024